Predicting and interpreting key features of refractory Mycoplasma pneumoniae pneumonia using multiple machine learning methods.

Journal: Scientific reports
Published Date:

Abstract

In recent years, the incidence of refractory Mycoplasma pneumoniae pneumonia (RMPP) has significantly risen, posing severe pulmonary and extrapulmonary complications, making early identification a challenge for clinicians. In this retrospective single-center study, we included patients diagnosed with Mycoplasma pneumoniae pneumonia in 2021, categorizing them into RMPP and non-RMPP groups. Univariate regression analysis initially identified variables associated with RMPP. Seven mainstream machine learning methods were then employed to construct predictive models, evaluated for reliability and robustness through tenfold cross-validation and sensitivity analysis. Ultimately, the optimal predictive model was selected using multidimensional metric assessments, and SHAP analysis identified key predictive factors related to RMPP. Twenty-nine factors from various dimensions were found to be associated with RMPP and used to build the predictive model. The XGBoost model demonstrated high predictive capability with an accuracy of 0.80 and an AUC of 0.93. Ten-fold cross-validation and sensitivity analysis confirmed the model's robustness and reliability. SHAP analysis interpreted the final model with 8 key features. These features include fever duration, macrolide treatment before hospitalization, severe Mycoplasma pneumoniae pneumonia, lactate dehydrogenase, neutrophil-to-lymphocyte ratio, alanine aminotransferase, peak fever, and extensive lung consolidation. This simple, effective predictive model enhances clinicians' understanding and aids early identification of RMPP.

Authors

  • Yuhan Jiang
    Tianjin Children's Hospital (Children's Hospital, Tianin University), Tianjin, China.
  • Xu Wang
    Weldon School of Biomedical Engineering, Purdue University, West Lafayette, IN 47907.
  • Li Li
    Department of Gastric Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China.
  • Yifan Wang
    School of Bioscience and Bioengineering, South China University of Technology, Guangzhou, China.
  • Xuelin Wang
    Gansu University of Chinese Medicine, Institute of Integrative Traditional Chinese and Western Medicine, Gansu University of Traditional Chinese Medicine, Provincial Key Laboratory of Molecular Medicine and Prevention and Treatment of Major Diseases with Traditional Chinese Medicine in Gansu Colleges and Universities, Lanzhou 730000, China.
  • Yingxue Zou
    Tianjin Children's Hospital (Children's Hospital, Tianin University), Tianjin, China. zouyingxue2015@tju.edu.cn.